City Of Hope's Joseph Alvarnas On CAR-T Real-World Use, Reimbursement

City of Hope hematologist/oncologist Joseph Alvarnas shares his perspectives on how CAR-T therapies are requiring new models of health care delivery and engagement with more kinds of stakeholders, during an interview at the recent ASH annual meeting.

Joseph Alvarnas at ASH — Joseph Alvarnas, City of Hope • Source: Courtesy of ASH

Longer-term data from studies of chimeric antigen receptor T-cell (CAR-T) therapies at the American Society of Hematology (ASH) meeting Dec. 1-4 in San Diego showed that patients with hematologic malignancies who've achieved remission are maintaining their response for more than a year.

The data are important in blood cancers where relapsed and refractory patients have run out of treatment options and have...